Produced from Elegen’s proprietary cell-free DNA production technology, ENFINIA Linear DNA provides unprecedented speed, length, and quality. Shipped in 6 to 8 business days and up to 7kb in length, ENFINIA DNA arrives NGS-verified with a 99.999% per base accuracy or 1:70,000 per base error rate, ready for immediate use without cloning. Unlock your synthetic biology workflows and save weeks to months on top of the personnel and equipment costs required for cell based cloning.
Join Dr Galit Meshulam-Simon, PhD from Elegen, and Dr Ben Steil, PhD from Daicel Arbor Biosciences live Wednesday, March 19, 2025 from 10:00 AM – 11:00 AM MST to discuss how combining Elegen’s ability to synthesize high-quality linear DNA up to 7kb and successful expression in cell-free systems such as myTXTL® Pro from Daicel, enable rapid, efficient and streamlined in vitro workflows.
In this upcoming webinar, it will be demonstrated that ENFINIA™ Linear DNA templates are functional in myTXTL® Pro and drive reporter gene expression at levels comparable to plasmid DNA templates. Live Q&A will follow. Register today to reserve your spot.
In this GEN webinar, Dr. Galit Meshulam-Simon and Dr. Matt Deaner from Elegen include case studies to demonstrate the advantages of using long, precise linear DNA over conventional small, error-prone fragments in building large, complex constructs.
Join the DDW Cell & Gene Therapy Showcase, a free online event hosted by DDW and co-sponsored by Benchling, Sartorius, Applied StemCell, and Elegen Bio.
In this event leading industry figures will outline areas of opportunity in CGT drug discovery & development sector as well as highlighting challenges facing the industry and how they can be overcome. It will feature presentations from experts in the field of cell and gene therapy drug development as well as a panel discussion.
Ravi Goel Lal from the Arnold Lab @Caltech joins Elegen’s Director of to discuss Active Learning-assisted Directed Evolution (ALDE) & how ENFINIA Linear DNA advanced their research.
In this webinar, members of the Elegen team will discuss improvements they have made to enable the cell-free synthesis of ENFINIA™ DNA constructs.
Matthew Hill, founder and CEO of Elegen joins a Drug Discovery World webinar to discuss the DNA supply bottleneck in mRNA drug development workflows and how Elegen uses an innovative approach to DNA synthesis to supply biopharma companies rapidly and reliably with long, accurate, dsDNA. With ENFINIA DNA, scientists can eliminate several steps of the traditional mRNA therapy screening and production processes to bring new therapies to market faster.
Evolution of DNA Supply, What Advances in DNA Synthesis will Unlock the Agile Development of Biology.
Chris Ghadban, Principal of Alix Ventures, moderates a panel of guests including Matthew Hill, Founder and CEO of Elegen, Jacob Becraft, Co-Founder and CEO of Strand Therapeutics, Tim Lu, Co-founder and CEO of Senti Bio, Cristina Butterfield, Sr. Director of Biochemistry at Metagenomi, and Patrick Boyle, Organism Designer at Ginkgo Bioworks, to discuss how a better solution for DNA synthesis will enable synthetic biologists to realize the promise of programmable biology.
Recorded at the BIO2023 International Convention, Julianna LeMieux, Deputy Editor and Chief of Genetic Engineering News moderates this discussion about the impacts and future of DNA synthesis and synthetic biology with industry thought leaders Matthew Hill, Founder and CEO of Elegen, Madoo Varma, VP of Business Development at DNA Script, Elaine Shapland, Sr. Director of Build Technology Development at Ginkgo Bioworks, and Daniel Arlo, CEO of Ansa.
Update on the latest advancements of Elegen’s products and technology, presented at the Synbiobeta 2023 conference, by Matthew Hill, Founder and CEO.
Subscribe to our latest news and product updates. (enter work email address only).
Elegen Corp
3565 Haven Ave, Suite 3
Menlo Park, CA 94025
© 2025 Elegen Corporation. All Rights Reserved.
